Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-based dual therapy duration in Helicobacter pylori eradication
ChiCTR2200057625Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vonoprazan and amoxicillin in Helicobacter pylori infection (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Helicobacter pylori eradication by urea breath test. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
vonoprazanamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2200057625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057625.